Non-fucosylated Anti-CTLA-4 (BMS-986218) + Degarelix Acetate vs. Degarelix Acetate Alone in Men With High-risk Localized Prostate Cancer

NCT04301414 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

26

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: BMS-986218 and Degarelix
DRUG: Degarelix

Sponsor

Columbia University

Collaborators

[object Object]
[object Object]